Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$37.34 USD
+1.42 (3.95%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $38.08 +0.74 (1.98%) 5:30 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Avidity Biosciences, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RNA 37.34 +1.42(3.95%)
Will RNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Other News for RNA
Avidity Biosciences (RNA) Completes Enrollment for Phase 3 DM1 Treatment Trial
Avidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
Avidity gets FDA breakthrough therapy status for DMD treatment
Avidity Biosciences (RNA) Secures Breakthrough Therapy Designation from FDA | RNA Stock News